Regen BioPharma Inc (OTCBB:RGBP) shares fell 12.59% on Tuesday to $0.125 but recovered 5.92% in after-hours trading. Share prices have been trading in a 52-week range of $0.07 to $0.22. The company has a market cap of $16.30 million at 134.55 million shares outstanding.
Regen BioPharma Inc is a biotechnology company that is focused on identifying undervalued regenerative medicine applications in the stem cell space. Aside from that, the company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its products include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC.
HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation.
In a press release on September 20, Regen BioPharma Inc shared that it was able to complete experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College.
We are delighted to discover that our lead compounds have a cellular effect, even though these compounds are not optimized yet,” said Harry M. Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma Inc. “These preclinical experiments firmly support our initial screening data which discovered these compounds. Now, it is a matter of optimizing these compounds to improve their efficacy.”
The results of the experiment indicated that the administration of Regen’s proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
